Dr Malcolm Lim is an experienced Cancer Biologist and His research interest spans cancer biology, biomarker discovery and theranostic nanomedicine.
He received his PhD from the University of Queensland (UQ) in 2022. His research, conducted in the labs of Professors Sunil Lakhani and Kristofer Thurecht, involved evaluating the efficacy of using nanomedicine for precision delivery of chemo- or radiotherapeutics against biomarkers in brain metastases. For this work, he developed a clinically-relevant brain metastasis mouse model. His research was recognised with the UQ Dean’s Award for Outstanding Thesis 2022. (DOIs: 10.1021/acs.molpharmaceut.3c00558, 10.3791/64216)
Currently, Malcolm serves as a Postdoctoral Research Fellow at the ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) and the Thurecht’s Lab at UQ-Centre for Advanced Imaging (CAI) in Australian Institute for Bioengineering and Nanotechnology (AIBN), where he will apply his multidisciplinary expertise to explore radiobiology and radiation-induced biological responses and to advance targeted pharmaceuticals for challenging cancers.
Prior to joining AMTAR, Malcolm served as a Postdoctoral Researcher where he investigated the molecular mechanisms underlying Early Breast Cancers at the Molecular Breast Pathology Lab, UQ-Centre for Clinical Research, under the mentorship of Professors Sunil Lakhani and Peter Simpson. Before his academic career, Malcolm had five years of experience as a histologist, which provided him with a broad skillset in the field.
Dr Malcolm’s research is well-documented in numerous publications in biomedical research journals despite his career stage, reflecting his passion to advancing cancer research.
Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).
